With this year holding great potential for the future of γδ T therapies, as we start to see the much anticipated proof of concept data, and the huge opportunity for the cell immunotherapy field to realise success in the solid tumor space, there are still many questions left to be answered to determine if γδ T therapies truly are the next generation of cancer immunotherapy. There is still a need to demonstrate both safety and efficacy of these therapies at a clinical level to bring to market effective solid tumor treatment for patients in need.

This workshop will discuss:
• Regulatory strategies to define EMA and FDA expectations
• Demonstrating and understanding nonclinical safety for a first-in-class immune activator is key to recruiting investigators and patients
• Defining target indications and patient selection criteria based on γ9δ2 T cell biology using translational research increases to probability of success